Katherine Vousden obtained a PhD from the Genetics department at the University of Leicester in 1996. Following a postdoctoral placement at the University of Sheffield, she has spent over 22 years in the biopharmaceutical industry – over 19 years of which in the field of antibody discovery and protein engineering. Her position prior to joining Charles River was as an Associate Director at MedImmune/AstraZeneca, where she managed a multidisciplinary team and led numerous large molecule programs through to candidate nomination. In early 2020 Katherine joined Charles River as a Science Director, to support the growth of large molecule capabilities and partnerships across the Discovery organization. She is currently Head of Large Molecule Research for our South San Francisco Antibody Discovery site.
- Review: Vousden KA, Clarke DL & Lowe DC (2013) Engineering approaches to develop the next generation of antibodies to respiratory targets. Inflamm Allergy Drug Targets 12:99-108 doi
- Vousden KA et al (2019) Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.
- Chen B, Vousden KA et al (2019) Humanised effector-null FcgRIIA antibody inhibits complex-mediated proinflammatory responses.